Table 1 Characteristics of included studies
|  | All studies, mean (range) or n (%) (n = 33) | Mixed ward + ICU studies, mean (range) or n (%) (n = 14) | ICU studies, mean (range) or n (%) (n = 19) |
|---|---|---|---|
Continent | |||
 - Europe | 28 (84.9%) | 12 (85.7%) | 16 (84.2%) |
 - USA | 3 (9.1%) | 1 (7.1%) | 2 (10.53%) |
 - Asia | 2 (6.1%) | 1 (7.1%) | 1 (5.26%) |
Study design | |||
 - Retrospective cohort | 19 (57.6%) | 8 (57.1%) | 11 (57.9%) |
 - Prospective cohort | 12 (36.4%) | 5 (35.7%) | 7 (36.84%) |
 - Cross-sectional | 2 (6.1%) | 1 (7.1%) | 1 (5.3%) |
NOS | |||
 - | 2 (6.1%) | 0 | 2 (10.5%) |
 - | 8 (24.2%) | 4 (28.6%) | 4 (21.1%) |
 - | 12 (36.4%) | 6 (42.9%) | 6 (31.6%) |
 - | 7 (21.2%) | 2 (14.3%) | 5 (26.3%) |
 - | 4 (12.1%) | 2 (14.3%) | 2 (10.5%) |
n total | 4009 | 2747 | 1262 |
n per study | 121 (10–785) | 196 (25–785) | 66 (10–184) |
n VTE total | 429 | 170 | 259 |
Age, years | 64 (57–69) [missing = 10] | 66 (61–71) [missing = 4] | 63 (57–70) [missing = 6] |
Women | 31.8% (13.8–48.3%) [missing = 8] | 34.2% (13.8–48.3%) [missing = 3] | 30.0% (16.7–45.8%) [missing = 5] |
CVD | 21.3% (8.8–52%) [missing = 19] | 23.0% (11.9–52%) [missing = 9] | 20.4% (8.8–48%) [missing = 10] |
HTN | 48.0% (32–84.6%) [missing = 17] | 43.0% (32–62.5%) [missing = 7] | 51.8% (38.2–84.6%) [missing = 10] |
DM | 26.8% (4–44.6%) [missing = 15] | 19.2% (8–30.8%) [missing = 6] | 32.9% (4–44.6%) [missing = 9] |
Body-mass index, kg/m2 | 28.9 (23.6–34.8) [missing = 18] | 27.0 (23.6–30) [missing = 8] | 30.2 (27.5–34.8) [missing = 10] |
Cancer | 6.2% (0–20%) [missing = 17] | 8.3% (3.5–20%) [missing = 6] | 4.0% (0–8%) [missing = 11] |
Personal history of VTE | 3.0% (0–7.6%) [missing = 19] | 2.9% (0–7.0%) [missing = 8] | 3.0% (0–7.6%) [missing = 11] |
Smoking | 19.1% (3.1–43.8%) [missing =24] | 15.6% (3.1–43.8%) [missing = 9] | 2.5% (1.8–3.0%) [missing = 15] |
Laboratory testing | |||
 - Baseline D-dimer, μg/L | 2352 (394–8300) [missing =14] | 1808 (458–3700) [missing = 6] | 2748 (394–8300) [missing = 8] |
 - Baseline fibrinogen, g/L | 6.5 (4.1–9) [missing =17] | 5.2 (4.8–5.9) [missing = 11] | 6.8 (4.1–9) [missing = 8] |
 - Baseline platelets, × 10 [9]/L | 233 (187–318) [missing = 18] | 235 (187–286) [missing = 8] | 232 (200–319) [missing = 10] |
Anticoagulation | |||
 - Chronic anticoagulation | 7.4% (0–26.9%) [missing = 21] | 6.8% (0–16%) [missing = 9] | 7.8% (0–27.0%) [missing = 12] |
 - Therapeutic anticoagulation during the study | 10.4% (0–69.2%) [missing =10] | 4.3& (0–16%) [missing = 6] | 13.6% (0–6.9%) [missing = 4] |
 - Prophylactic anticoagulation during the study | 83.8% (0–100%) [missing = 11] | 80.4% (20–100%) [missing = 5] | 85.9% (30.8–100%) [missing = 4] |
ICU | |||
 - ICU hospitalization | 76.4% (6.3–100%) [missing = 7] | 26.6% (6.3–53.8%) [missing = 5] | 100% (100–100%) |
 - Mechanical ventilation | 67.5% (10–100%) [missing = 11] | 25.2% (11.3–25.6%) [missing = 8] | 83.3% (10–100%) [missing = 3] |
 - Use of vasopressors | 64.2% (32.1–88.5%) [missing = 25] | - [missing = 14] | 64.2% (32.1–88.5%) [missing = 11] |
 - Hemodialysis | 22.9% (14.7–37.1%) [missing = 27] | - [missing = 14] | 22.9% (14.7–37.1%) [missing = 13] |
 - ECMO | 16.9% (0–100%) [missing = 24] | 0% (0–0%) [missing = 13] | 19.1% (0–100%) [missing = 11] |
